GREENER Pharmaceuticals for More Sustainable Healthcare.


Journal

Environmental science & technology letters
ISSN: 2328-8930
Titre abrégé: Environ Sci Technol Lett
Pays: United States
ID NLM: 101628367

Informations de publication

Date de publication:
13 Sep 2022
Historique:
received: 01 07 2022
revised: 11 08 2022
accepted: 11 08 2022
entrez: 19 9 2022
pubmed: 20 9 2022
medline: 20 9 2022
Statut: ppublish

Résumé

Medicines are essential to human health but can also impact the aquatic and terrestrial environment after use by patients and release via excreta into wastewater. We highlight the need for a GREENER approach to identify and meet important environmental criteria, which will help reduce the impact of medicinal residues on the environment. These criteria include effect reduction by avoiding nontarget effects or undesirable moieties, exposure reduction via lower emissions or environmental (bio)degradability, no PBT (persistent, bioaccumulative, and toxic) substances, and risk mitigation. With all of these criteria, however, patient health is of primary importance as medicines are required to be safe and efficacious for treating diseases. We discuss the feasibility of including these criteria for green by design active pharmaceutical ingredients in the process of drug discovery and development and which tools or assays are needed to accomplish this. The integrated GREENER approach can be used to accelerate discussions about future innovations in drug discovery and development.

Identifiants

pubmed: 36118957
doi: 10.1021/acs.estlett.2c00446
pmc: PMC9476650
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

699-705

Informations de copyright

© 2022 American Chemical Society.

Déclaration de conflit d'intérêts

The authors declare no competing financial interest.

Références

Proc Natl Acad Sci U S A. 2022 Feb 22;119(8):
pubmed: 35165193
Environ Pollut. 2018 Aug;239:129-146
pubmed: 29653304
Environ Sci Technol. 2016 Jan 19;50(2):525-41
pubmed: 26619126
Int J Toxicol. 2007 Jan-Feb;26(1):13-23
pubmed: 17365142
Proc Natl Acad Sci U S A. 2007 May 22;104(21):8897-901
pubmed: 17517636
Nucleic Acids Res. 2018 Jan 4;46(D1):D930-D936
pubmed: 29140522
Sci Total Environ. 2021 Dec 15;800:149412
pubmed: 34391154
Environ Toxicol Chem. 2016 Apr;35(4):823-35
pubmed: 26666847
Br J Clin Pharmacol. 2022 Aug 24;:
pubmed: 36000992
Chem Rev. 2022 Feb 9;122(3):3637-3710
pubmed: 34910451
Nat Rev Drug Discov. 2018 Mar;17(3):167-181
pubmed: 29348681
Nature. 2017 Mar 29;543(7647):S47
pubmed: 28355188

Auteurs

Caroline T A Moermond (CTA)

Centre for Safety of Substances and Products (VSP), National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA Bilthoven, The Netherlands.

Neele Puhlmann (N)

Institut für Nachhaltige Chemie und Umweltchemie, Leuphana Universität Lüneburg, Universitätsallee 1, C13.205, 21335 Lüneburg, Germany.

A Ross Brown (AR)

Biosciences, College of Life and Environmental Sciences, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter, Devon EX4 4QD, U.K.

Stewart F Owen (SF)

AstraZeneca, Global Sustainability, Silk Road, Macclesfield, Cheshire SK10 2NA, U.K.

Jim Ryan (J)

GSK, Environment, Health & Safety, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, U.K.

Jason Snape (J)

AstraZeneca, Global Sustainability, Silk Road, Macclesfield, Cheshire SK10 2NA, U.K.

Bastiaan J Venhuis (BJ)

Centre for Health Protection (GZB), National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA Bilthoven, The Netherlands.

Klaus Kümmerer (K)

Institut für Nachhaltige Chemie, Leuphana Universität Lüneburg, Universitätsallee, 1/C13.311b, 21335 Lüneburg, Germany.

Classifications MeSH